Thrombotic thrombocyopenic purpura (TTP) is a life-threatening autoimmune disease in which small blood clots or microthrombi form in the arterioles. The formation of these is caused by autoantibodies against the ADAMTS13 enzyme, which, in healthy individuals, binds to von Willebrand factor (vWF) multimers and degrades them. With reduced ADAMTS13 activity, vWF multimers accumulate in the bloodstream and form platelet-rich clots, which can cause ischemia and organ failure in patients with TTP. Treatment options for TTP are limited and can many times be unpleasant for the patient due to possible side effects, which is why we focused on finding new therapeutic approaches for treating TTP in this master's thesis. Our initial goal was to identify short peptides that would prevent the interaction between anti-ADAMTS13 autoantibodies and ADAMTS13 antigen, thus preventing further immune reactions in patients with TTP. For detection of peptides we chose the phage display method, where we performed an affinity selection from two commercial bacteriophage libraries: the Ph. D.TM – 7AK linear peptide library and the Ph. D.TM – C7C cyclic peptide library. Our target were anti-ADAMTS13 antibodies, isolated from the serum of immunized animals. We immobilized the target onto magnetic particles, bound the phage library to it and eluted the phages with high binding affinity. We used two different elution techniques; specific with antigen ADAMTS13 and non-specific with a low pH buffer. We amplified the phage eluate in E.coli and isolated the phage DNA from bacterial cells, which we sent to sequencing. We also performed an ELISA test, where we evaluated the binding specifity of isolated bacteriophage clones to the anti-ADAMTS13 autobodies. We processed the results with bioinformatics software and arranged the obtained sequences into peptide clusters based on their motifs. Within the clusters we identified major epitopes and epitope mimetics of the ADAMTS13 antigen, as well as designed peptide decoys. In future research, it would be interesting to investigate whether those decoys can prevent the interaction between autoantibodies and the autoantigen, and evaluate their therapeutic potential in the treatment of TTP.
|